Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

3.8%

1 terminated/withdrawn out of 26 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

12%

3 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

7 recruiting1 with results

Enrollment Performance

Analytics

N/A
11(47.8%)
Phase 2
6(26.1%)
Phase 1
3(13.0%)
Phase 3
3(13.0%)
23Total
N/A(11)
Phase 2(6)
Phase 1(3)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT05376527Phase 1Completed

Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact

Role: collaborator

NCT07258680Phase 3Enrolling By Invitation

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

Role: lead

NCT06418789Phase 2Recruiting

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

Role: lead

NCT05468827Not ApplicableCompleted

ICG Fluorescence Guided Lymph Node Mapping for Determination of Bowel Resection Margins in Colon Cancer

Role: lead

NCT06043947Active Not Recruiting

Survival Monitoring in Russian Cancer Registries

Role: lead

NCT06669013Phase 3Recruiting

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Role: lead

NCT05539677Recruiting

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

Role: lead

NCT06299852Not ApplicableRecruiting

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

Role: lead

NCT06229340Phase 2Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Role: lead

NCT06133699Not ApplicableUnknown

Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors

Role: lead

NCT05757466Phase 2Unknown

Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma

Role: collaborator

NCT04592289Not ApplicableUnknown

Short-term Outcomes of Full Bowel Preparation (MBP+OA) for Rectal Resections for Cancer Versus MBP Alone

Role: lead

NCT05546892Not ApplicableUnknown

Short-term Outcomes of Full Bowel Preparation (MBP+OA) for Colon Cancer Resections Versus no Bowel Preparation

Role: lead

NCT04293796Not ApplicableRecruiting

Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)

Role: lead

NCT05392634Phase 3Unknown

Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery

Role: lead

NCT03009227Not ApplicableUnknown

Study of Oncological Outcomes of D3 Lymph Node Dissection in Colon Cancer

Role: lead

NCT04870567Not ApplicableUnknown

HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer

Role: lead

NCT04783649Unknown

Clinical Validation of Cervical Cancer Screening Methods

Role: lead

NCT04747717Not ApplicableUnknown

Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer

Role: lead

NCT04330456Not ApplicableRecruiting

Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy

Role: lead